Patrick Johnson is the Chief Business Officer at Sydenxis. Prior to this role, Patrick was the Vice President of Corporate and Business Development at Allergan, a publicly-traded, large-cap pharmaceutical company. At Allergan, Patrick was responsible for corporate partnerships and mergers and acquisitions in ophthalmology, Allergan’s largest therapeutic area, and also drug delivery. Prior to Allergan, Patrick was a co-founder of Chimeros, a biotechnology start-up company founded in Santa Barbara in 2005 where he was Vice President of Business Development in addition to leading scientific teams as Director of Biology. Before co-founding Chimeros, Patrick was an adjunct faculty member at the University of California, Santa Barbara where he was simultaneously conducting research in the Center for the Study of Macular Degeneration while teaching classes in Neurobiology, Developmental Biology, Introductory Biology, and Biotechnology and Society. Patrick holds a B.S. in Biopsychology and a Ph.D. in Molecular, Cellular and Developmental Biology, both from USCB. His doctoral research focused on the development of visual pathways in mammals and his post-doctoral research focussed on diseases of the eye, spanning both acute injury (retinal detachment) and chronic disease (age-related macular degeneration).
Ken is an M.D. with over 30 years of experience working with biomedical companies. He has founded seven companies and was Chairman/CEO of six of these. He was a General Partner at LVP Life Science Ventures (formerly Latterell Venture Partners) for over a decade, and previously was a General Partner at Windamere Venture Partners.
He formerly was CEO and Chairman of Sytera Inc. which merged with Sirion Therapeutics, an ophthalmology specialty pharmaceutical company. Prior to Sytera, Ken was a co-founder and CEO of NovaCardia, a company acquired by Merck after positive phase 2 data. Prior to NovaCardia, Ken was a founder, Chairman, and CEO of Santarus (NASDAQ:SNTS), which was acquired by Salix Pharmaceuticals. Additionally he was Chairman and CEO of Converge Medical, a medical device company developing a sutureless anastamosis system for vein grafts in coronary artery by-pass surgery.
Ken started his career as a founder, Chairman and CEO of Molecular Biosystems, where he was responsible for the development and approval of AlbunexTM and OptisonTM, the first two ultrasound contrast agents to be approved in the U.S. He currently sits on the boards of Evoke Pharma, OrphoMed, and Quidel, Inc.
Ken holds an M.D. from Northwestern University and trained in pathology at Duke University. He is an inventor on over 30 patents and patent applications and has authored or co-authored over 30 publications.
Jacqueline Johnson, Ph.D. is co-founder and Chief Operating Officer of Sydnexis Inc. Her role includes but is not limited to the management of finance, manufacturing, preclinical toxicology studies, analytical chemistry, and quality programs for the Company.
Prior to Sydnexis, Dr. Johnson was President of Development and Strategic Consulting LLC for 10 years (2004-2014). This firm offered management expertise to biotechnology clients in the areas of regulatory and clinical affairs. In addition, Dr. Johnson held interim management roles in biotech start-ups as acting CEO of Trinity Pharmaceutical and acting COO of Revision Therapeutics.
Dr. Johnson served as President and CEO of Ferx Inc. from 1996-2004. Ferx was a biotechnology company focused on the development of their proprietary product Magnetic Targeted Carriers which were used to deliver potent chemotherapy compounds to specific tumor sites in the body. Ferx performed clinical trials worldwide including Europe and was the first company to do trials with an unmarketed product in China starting in 1998.
Dr. Johnson was Vice President of Operations at Signal Pharmaceuticals from 1992-1995. Signal was eventually purchased by Celgene. Before that she was Director of Product Development at Amylin Pharmaceuticals (1989-1992) and she started her career as Sr. Scientist of Molecular BIolkogy at Hybritech Inc. in 1986.
Dr. Johnson received both a Bachelor and a Master degree from the University of California, Berkeley, a Ph.D. from Stanford University School of Medicine (Genetics) and as a Damon Runyon Fellow did her Post-doctoral work at The Salk Institute.
Gregory Ostrow, MD, is an ophthalmologist with fellowship training in pediatric ophthalmology and adult strabismus. He has a clinical interest in providing myopia control, as well as treating strabismus (wandering eyes) in both children and adults, amblyopia (weak or lazy eye), blocked tear ducts, cysts around the eye (orbital dermoids), cataracts, nystagmus (jiggling eyes), pediatric glaucoma, pediatric ptosis (drooping eyelids) and pediatric uveitis (an inflammatory eye disease). Dr. Ostrow also offers assessments of visual development and treatment for children with special needs.
Dr. Ostrow and his office staff work diligently to provide patients with accessible and exemplary care, as well as a sense of comfort. He understands the importance of communication and compassion, and he works to encourage dialogue that helps establish trust and lasting partnerships with his patients and their parents.
In addition to his clinical work, Dr. Ostrow is involved with a number of professional organizations. He is a fellow of the American Academy of Pediatrics as well as the American Academy of Ophthalmology. Additionally, Dr. Ostrow is member of the American Association for Pediatric Ophthalmology and Strabismus. He serves on the Board of Directors and is a volunteer surgeon for Fresh Start Surgical Gifts. Dr. Ostrow also sits on the Board of Directors for Vision of Children Foundation.
Dr. Ostrow is an editor for the journal International Ophthalmology Clinics and he has written several book chapters, including “The Pediatric Eye Exam” chapter in Harley’s Pediatric Ophthalmology. He is a frequent lecturer on numerous pediatric eye diseases.
He also has a clinical research interest in myopia control. Dr. Ostrow was awarded a Scripps Clinic research grant to study eye movement recordings in children, many of his ophthalmic research findings have been presented nationally and printed in medical journals.
Dr. Ostrow has been named one of San Diego County Medical Society’s Top Doctors for the past seven years and has been honored as a Castle Connolly Top Doctor for the past six years. He has also been a Patients’ Choice award winner for the past nine years and regularly treats patients who travel from around the United States and abroad.
A father of two girls and a seasoned outdoorsman, Dr. Ostrow enjoys spending time with his family, surfing, snowboarding, mountain climbing, traveling to exotic locations, growing fruits and vegetables and cooking gourmet food. He enjoys sharing his passion for the outdoors with his daughters and serving the San Diego community as a physician.
Jon is a Partner at Medicxi and has been with the firm since its inception in 2016. Prior to joining Medicxi, Jon was an Associate at Index Ventures for two years, having joined in 2014. He led Medicxi’s investment in Synthorx and currently serves on the boards of a number of portfolio companies, including Palladio Biosciences, Xenikos, Z-Factor, UltraHuman and Sydnexis. Jon was also previously a director of Impact Biomedicines (acquired by Celgene).
Prior to Index, Jon was a life sciences strategy consultant at ClearView Healthcare Partners.
Jon received a Ph.D. in Biochemistry and Biophysics from the University of North Carolina at Chapel Hill and conducted postdoctoral research at MIT.
Zach Scheiner is a Principal on the Investment Team at RA Capital Management. Zach works on both public and private investments and serves as a Board Director for Sydnexis, Inc. Previously, Zach covered the neurology, ophthalmology, and dermatology landscapes. Zach holds a BS in Molecular Biophysics and Biochemistry from Yale University, and a PhD in Neurobiology and Behavior from the University of Washington. His doctoral research focused on the regulation of the ERK/MAPK pathway by adenylyl cyclases during long-term memory formation and sensitization to drugs of abuse. Zach previously worked as a Science Officer at the California Institute for Regenerative Medicine.
Kevin is a co-founder and Partner at Medicxi. Prior to Medicxi, Kevin was a partner at Index Ventures for 13 years, having joined the firm in 2003. Kevin originated Index’s first asset-centric investment in PanGenetics (acquired by Abbott) and led Medicxi’s investment in Impact Biomedicines (acquired by Celgene). Kevin currently serves on the boards of a number of portfolio companies, including Levicept, Capella BioScience, UltraHuman and ApcinteX.
Prior to joining Index, Kevin was with Cambridge Antibody Technology (CAT). During his tenure at CAT, he was appointed Head of Research in 1994 and then Research Director and Chief Technology Officer in 1997. Kevin led the development of CAT's platform technologies and oversaw their application in the discovery of a number of human antibodies - two of which are now marketed worldwide: Humira (by Abbott Pharmaceuticals) and Benlysta (by GlaxoSmithKline). Kevin was part of the management team that floated CAT on the London Stock Exchange (subsequently acquired by AstraZeneca).
Kevin received a BSc in Molecular Biology from Edinburgh University and a PhD in Pathology from Cambridge University. He also acts as chairman of Crescendo Biologics and sits on the strategic advisory committee of Hilleman Laboratories.
Dr. Grunberg is a Managing Director at Longitude Capital. Prior to joining Longitude Capital in 2012, Dr. Grunberg was a Principal at Rho Ventures and an Engagement Manager at McKinsey & Company. Dr. Grunberg is a board-certified physician in Internal Medicine and completed his residency at Cornell’s New York Presbyterian Hospital. He has maintained a limited clinical practice in Internal Medicine and affiliations with UCSF and Kaiser Permanente. Dr. Grunberg currently serves on the boards of BAROnova, Kala Pharmaceuticals (KALA), 89bio and WelbeHealth. He is also a board observer at Sydnexis. He previously served on the board of California Cryobank (acquired by GI Partners) and led Longitude’s investment in Practice Fusion (acquired by Allscripts). While at Rho Ventures he served on the board of AqueSys (acquired by Allergan) and was a board observer at both SARCode Bioscience (acquired by Shire) and PHT (acquired by ERT). Dr. Grunberg holds an M.D. and an M.B.A from Duke University where he was a Fuqua Scholar and an A.B. in Economics and English from Amherst College.